Loading...
Your medical briefing
Stay current.
Stay focused.
Research, guidelines, and safety alerts for your specialty.
Latest updates
Browse recent updates across specialties.
Your medical briefing
Research, guidelines, and safety alerts for your specialty.
Browse recent updates across specialties.
A population-based study tracking hospitalized first-ever strokes across six periods from 1993/4 to 2020 found stroke incidence in adults aged 20-54 nearly doubled, driven largely by ischemic stroke, while incidence declined in older adults over the same period. The study also reported rising rates of hypertension, diabetes, atrial fibrillation, and substance use among young stroke patients over time, alongside a modest decline in 30-day case fatality, attributed mainly to improved outcomes in hemorrhagic stroke subtypes.
A population-wide matched cohort study using linked administrative health data from Ontario, Canada (2002-2022) examined dementia risk after TIA in over 113,000 patients compared with matched population controls and stroke patients. The study reported dementia in 19.3% of TIA patients over a mean follow-up of 7.11 years, with dementia risk highest in the first year (HR 1.75) and remaining elevated over 20 years (overall HR 1.34) compared with controls; risk converged with that of stroke patients after 5 years. The authors state dementia occurred far more frequently than incident stroke after TIA, highlighting cognitive decline as a major long-term complication.
Pooled data from two prospective studies and an expanded-access program (27 total participants) evaluated etuvetidigene autotemcel, an autologous lentiviral gene therapy, in patients with Wiskott-Aldrich syndrome. Over a median follow-up of 5.7 years, overall survival was 96% at both 1 and 5 years, with one death reported, and rates of severe infections and moderate-to-severe bleeding events decreased compared with the year before treatment; no insertional oncogenesis was observed, and the most common grade 3 or higher adverse event was central venous catheter-related infection. The authors report these findings as consistent with sustained clinical benefit.
A phase 1 study evaluated anitocabtagene autoleucel (anito-cel), a BCMA-directed CAR T-cell therapy using a novel d-domain binder, in 38 patients with heavily pretreated relapsed or refractory multiple myeloma. The trial reported a 100% overall response rate with 79% complete responses, median progression-free survival of 30.2 months, and low rates of severe cytokine release syndrome or neurotoxicity at the recommended phase 2 dose. In vitro comparisons found the ddBCMA binder produced less cytokine release than a dual-VHH binder corresponding to ciltacabtagene autoleucel while maintaining similar cytotoxicity.
Physicians at Rush University Medical Center report seeing more medical emergencies and patients seeking addiction treatment related to 7-Hydroxymitragynine (7-OH), a concentrated kratom derivative sold at smoke and vape shops. Dr. Antonia Nemanich, an emergency medicine and medical toxicology physician at Rush, said 7-OH acts similarly to an opioid and noted concerns about its addictive potential and inconsistent concentrations across products. The article states Rush has not treated many overdose cases involving 7-OH to date.
A ToxIC NOSE report from the American College of Medical Toxicology describes cychlorphine, a non-fentanyl synthetic opioid of the orphine class that emerged in the US in late 2025 and has been detected in the illicit drug supply in at least 10 states, most prevalently Ohio, Texas, and Tennessee. The report states cychlorphine is thought to be as potent or more potent than fentanyl, often co-occurs with other opioids, stimulants, or novel benzodiazepines, and carries a significant risk of fatal respiratory depression in overdose. The report also notes that standard hospital urine opiate and fentanyl screens, as well as fentanyl or nitazene test strips, will not detect cychlorphine, based on a case identified through the ToxIC Fentalog Study.
Baxter Healthcare Corporation issued a Class I recall for Dextrose Injection, USP, 70%, 2000 mL bags (NDC 00338-0719-06) due to the presence of particulate matter identified as stainless steel particles in the solution. The FDA classifies this as a Class I recall, its most serious category.
The FDA reported a Class II recall of Broadway Joe's Pain Cream, a topical product containing CBD isolate, hempseed oil, and histamine dihydrochloride, distributed in 4 oz jars under NDC 83088-8120-6. The recall was initiated due to current good manufacturing practice (CGMP) deviations, specifically potential contamination of the raw material used in the product.
Optimal Balance Pharmacy issued a Class I recall of its Glutathione 200 mg/mL sterile multidose injection vials, intended for IM or IV use, after out-of-specification results were obtained for bacterial endotoxin, indicating microbial contamination of the sterile product. The recall notice does not specify further clinical outcomes but classifies the issue under microbial contamination of sterile products.
Baxter Healthcare Corporation has issued a Class II recall for Vancomycin Injection, USP in 5% Dextrose, 1 g per 200mL (5 mg/mL), supplied in GALAXY Single-Dose Containers under NDC 0338-3552-48. The FDA recall notice cites current good manufacturing practice (CGMP) deviations as the reason for the action.
The FDA recall notice reports a Class II recall by Baxter Healthcare Corporation for Vasopressin in 0.9% Sodium Chloride Injection, 40 units per 100 mL (0.4 units/mL), supplied in 100 mL single-dose containers under NDC 0338-9647-12. The notice attributes the recall to current good manufacturing practice (CGMP) deviations.
Baxter Healthcare Corporation has issued a Class II recall for Vancomycin Injection, USP, in 0.9% Sodium Chloride (1g per 200 mL, 5 mg/mL) supplied in GALAXY Single-Dose Containers, NDC 0338-3583-01. The recall was initiated due to current Good Manufacturing Practice (CGMP) deviations, as reported in the recall notice.
The FDA recall notice describes a Class II recall of Baxter Healthcare's Nexterone (amiodarone HCl) 360 mg/200 mL (1.8 mg/mL) injection in GALAXY Single-Dose Containers, NDC 43066-360-20. The notice states the recall is due to current Good Manufacturing Practice (CGMP) deviations. No further details on the specific defect or associated clinical risk are provided in the source text.
A Class II recall has been issued for Mylan Pharmaceuticals' Prasugrel Tablets, USP, 10mg (30-count bottles, NDC 0378-5186-93). The recall notice states the product failed dissolution specifications and did not meet 18-month stability testing acceptance criteria.
Mylan Pharmaceuticals Inc has issued a Class II recall for Mycophenolate Mofetil for Injection, USP, 500 mg/vial (NDC 67457-386-81 carton, NDC 67457-386-00 vial), citing failed dissolution specifications. The affected product is sold as 4 single-dose vials manufactured for Mylan Institutional LLC and made in India.
Baxter Healthcare Corporation has issued a Class II recall for Clindamycin Phosphate in 0.9% Sodium Chloride Injection, 600 mg per 50 mL (12 mg/mL), supplied in 50 mL single-dose GALAXY containers under NDC 0338-9549-50. The recall notice cites CGMP deviations as the reason for the action.
Baxter Healthcare Corporation has issued a Class II recall for Clindamycin Injection USP in 5% Dextrose, 900 mg/50 mL (18 mg/mL), supplied in GALAXY 50 mL single dose containers (NDC 43066-995-24). The recall was initiated due to current good manufacturing practice (CGMP) deviations, as reported in the recall notice. No additional details on the specific deviation or clinical impact were provided in the source text.
Baxter Healthcare Corporation has issued a Class I recall for its 0.9% Sodium Chloride Injection USP, 500 mL, in VIAFLEX plastic containers (NDC 0338-0049-03), packaged 24 units per case. The recall notice states the product contains particulate matter identified as fiberglass. FDA classifies this as a Class I recall, indicating the most serious recall category.